Revlimid (lenalidomide)

DRUG6 trials

Sponsors

Millennium Pharmaceuticals, Inc., Universitätsklinikum Hamburg-Eppendorf, Columbia University, Celgene, National Cancer Institute (NCI)

Conditions

Burkitt LymphomaDiffuse Large B-Cell LymphomaLymphomaMultiple MyelomaMyelodysplastic SyndromeNon-Hodgkin Lymphoma

Phase 1

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

CompletedNCT00507442

Millennium Pharmaceuticals, Inc.Multiple Myeloma

Start: 2007-08-31End: 2010-11-30Updated: 2013-07-26

Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma

CompletedNCT00778752

Universitätsklinikum Hamburg-EppendorfMultiple Myeloma

Start: 2009-04-30End: 2013-12-31Updated: 2015-05-13

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

RecruitingNCT03223610

National Cancer Institute (NCI)Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Lymphoma +1

Start: 2018-02-09End: 2027-12-01Target: 155Updated: 2026-09-16

Phase 2

Revlimid in Transfusion Dependent Patients

CompletedNCT01178814

Columbia UniversityMyelodysplastic Syndrome

Start: 2009-06-01End: 2022-12-07Updated: 2024-06-24

Unknown Phase

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

TerminatedNCT01947309

CelgeneMultiple Myeloma

Start: 2013-11-30End: 2016-09-30Updated: 2017-01-12

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

CompletedNCT03106324

CelgeneMultiple Myeloma

Start: 2017-03-31End: 2026-01-14Updated: 2026-05-28

Related Papers

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

New England Journal of Medicine2024-06-1956 citations

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Blood2022-11-151 citations

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Blood2019-11-13

PS1421 HONEUR (HEAMATOLOGY OUTCOMES NETWORK IN EUROPE) – DISTRIBUTED STATISTICS IN A FEDERATED MODEL TO SUPPORT REAL WORLD DATA RESEARCH IN HEMATOLOGY

HemaSphere2019-06-013 citations

[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].

PubMed2017-07-012 citations

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

2012-03-15328 citations

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.

2010-05-2759 citations